{"schema_version":"secwatch.filing_event.v1","accession":"0001757073-25-000026","form_type":"8-K","ticker":"NVST","cik":"0001757073","company_name":"Envista Holdings Corp","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.602308+00:00","generated_at":"2026-05-23T00:50:18.289554+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Envista Q1 sales $617M, adj. EPS $0.24, maintains 2025 guidance","bullets":["Sales $617M, core sales +0.2% YoY; net income $18M, adjusted net income $42M.","EPS $0.10, adjusted EPS $0.24 (ahead of expectations); adj. EBITDA $79M (12.8% margin).","Operating cash flow $0M, free cash flow ($5)M vs $29M last year; repurchased 1.1M shares for $19M.","Maintains FY2025 outlook: core sales growth 1-3%, adj. EPS $0.95-$1.05, adj. EBITDA margin ≈14%.","Growth in Consumables, Nobel Biocare, Spark; soft Diagnostics; China ortho down due to VBP preparations."],"urls":{"canonical":"https://secwatch.observer/filing/0001757073-25-000026","json":"https://secwatch.observer/filing/0001757073-25-000026.json","markdown":"https://secwatch.observer/filing/0001757073-25-000026.md","text":"https://secwatch.observer/filing/0001757073-25-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757073/000175707325000026/0001757073-25-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757073/000175707325000026/nvst-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:50:18.289554+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}